Investigation of the effect of Deferoxamine preconditioning on VEGF, ANGP1, and TFGβ1 gene expression in diabetic adipose derived stem cells (ADSCs)

Subject Areas : Journal of Comparative Pathobiology

راضیه Tajali ¹ (Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.)
اکرم Eidi ² (Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.)
حسین Ahmadi Tafti ³ (Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center Hospital, Tehran University of Medical Sciences, Tehran, Iran.)
عبدالرضا Pazouki ⁴ (Minimally Invasive Surgery Research Center, Iran University of Medical Sciences Tehran, Iran)
A.M Sharifi ⁵ (- Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran. -Razi Drug Research Center, and Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. -Tissue Engineering Group, (NOCERAL), Department of Orthopedics Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia)

Received: 2023-05-24 Accepted : 2023-08-06 Published : 2023-08-23

Keywords: Adipose tissue-derived stem ce, Deferoxamine, Angiogenesis,

Abstract :

Adipose tissue-derived stem cells (ADSCs) have been considered a promising treatment for diabetic wound repair. However, the effectiveness of autologous ADSC-derived therapy for diabetic patients needs to be improved. The aim of this study was to investigate the effect of pretreatment with deferoxamine on the expression of the angiogenic genes in diabetic ADSCs preconditioned with deferoxamine. In this experimental study, abdominal adipose tissue was taken from three patients with type 2 diabetes and three healthy individuals, and stem cells derived from adipose tissue were extracted by the enzymatic method. Diabetic ADSCs were treated with 75, 150, and 300 μM deferoxamine concentrations for 24 and 48 hours. Then, the cell survival rate was evaluated using the WST1 test and the expression level of VEGF, ANGP1, and TFGβ1 genes in normal, diabetic, and diabetic ADSCs treated with deferoxamine using the Real-time PCR technique. The data were analyzed using Prism statistical software. Our results showed that the expression levels of VEGF, ANGP1 and TGFβ1 genes in diabetic samples were significantly decreased compared to the normal group (P<0.05). However, the expression level of all three genes after treating the cells with concentrations of 150 and 300 μM deferoxamine for 24 hours was significantly increased compared to the untreated diabetic group (P<0.05). Our results showed that deferoxamine significantly increases the expression of VEGF, ANGP1, and TGFβ1 in diabetic ADSCs and increases their angiogenic capacity.

References:

1.Gao S, Zhang Y, Liang K, Bi R, Du Y. Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes. Stem Cells International. 2022;2022. Available from: doi: 10.1155/2022/8637493.

2. Spampinato SF, Caruso GI, De Pasquale R, Sortino MA, Merlo S. The treatment of impaired wound healing in diabetes: looking among old drugs. Pharmaceuticals. 2020;13(4):60. Available from: doi: /10.3390/ph13040060.

3. El Hage R, Knippschild U, Arnold T, Hinterseher I. Stem Cell-Based Therapy: A Promising Treatment for Diabetic Foot Ulcer. Biomedicines. 2022;10(7):1507. Available from: doi: 10.3390/biomedicines10071507.

4. Blumberg SN, Berger A, Hwang L, Pastar I, Warren SM, Chen W. The role of stem cells in the treatment of diabetic foot ulcers. Diabetes research and clinical practice. 2012;96(1):1-9. Available from: doi:10.1016/j.diabres.2011.10.032.

5. Liu R, Dong R, Chang M, Liang X, Wang HC. Adipose-derived stem cells for the treatment of diabetic wound: from basic study to clinical application. Frontiers in Endocrinology. 2022;13. Available from: doi: 10.3389/fendo.2022.882469.

6. Cianfarani F, Toietta G, Di Rocco G, Cesareo E, Zambruno G, Odorisio T. Diabetes impairs adipose tissue–derived stem cell function and efficiency in promoting wound healing. Wound repair and regeneration. 2013;21(4):545-53. Available from: doi: 10.1111/wrr.12051.

7. Rennert RC, Sorkin M, Januszyk M, Duscher D, Kosaraju R, Chung MT, et al. Diabetes impairs the angiogenic potential of adipose-derived stem cells by selectively depleting cellular subpopulations. Stem cell research & therapy. 2014;5(3):1-12. Available from: doi: 10.1186/scrt468.

8. Noronha NdC, Mizukami A, Caliári-Oliveira C, Cominal JG, Rocha JLM, Covas DT, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem cell research & therapy. 2019;10(1):1-21. Available from: doi: 10.1186/s13287-019-1224-y.

9. Liu GS, Peshavariya HM, Higuchi M, Chan EC, Dusting GJ, Jiang F. Pharmacological priming of adipose‐derived stem cells for paracrine VEGF production with deferoxamine. Journal of tissue engineering and regenerative medicine. 2016;10(3):E167-E76. Available from: doi: 10.1002/term.1796.

10. Zimna A, Kurpisz M. Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies. BioMed research international. 2015;2015. Available from: doi: 10.1155/2015/549412.

11. Sun J, Shen H, Shao L, Teng X, Chen Y, Liu X, et al. HIF-1α overexpression in mesenchymal stem cell-derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis. Stem Cell Research & Therapy. 2020;11:1-13. Available from: doi: 10.1186/s13287-020-01881-7.

12. Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes & cancer. 2011;2(12):1117-33. Available from: doi: 10.1177/1947601911423654.

13. Mehrabani M, Najafi M, Kamarul T, Mansouri K, Iranpour M, Nematollahi M, et al. Deferoxamine preconditioning to restore impaired HIF‐1α‐mediated angiogenic mechanisms in adipose‐derived stem cells from STZ‐induced type 1 diabetic rats. Cell proliferation. 2015;48(5):532-49. Available from: doi: 10.1111/cpr.12209.

14. Präbst K, Engelhardt H, Ringgeler S, Hübner H. Basic colorimetric proliferation assays: MTT, WST, and resazurin. Cell viability assays: methods and protocols. 2017:1-17. Available from: doi: 10.1007/978-1-4939-6960-9_1.

15. Zhang J, Liu Y, Chen Y, Yuan L, Liu H, Wang J, et al. Adipose-derived stem cells:current applications and future directions in the regeneration of multiple tissues. Stem Cells International. 2020;2020. Available from: doi: Available from: doi: 10.1155/2020/8810813.

16. Desjardins P, Conklin D. NanoDrop microvolume quantitation of nucleic acids. JoVE (Journal of Visualized Experiments). 2010(45):e2565.Available from: doi: 10.3791/2565.

17. Tu H, Avenarius MR, Kubatko L, Hunt M, et al. Distinct Patterns of Emergence of SARS-CoV-2 Spike Variants including N501Y in Clinical Samples in Columbus Ohio. BioRxiv. 2021; Available from: doi: 10.1101/2021.01.12.426407

18. Thornton B, Basu C. Rapid and simple method of qPCR primer design. PCR primer design. 2015:173-9.

19. Rassouli A, Shihmani B, Mehrzad J, Shokrpoor S. The immunomodulatory effect of minocycline on gene expression of inflammation related cytokines in lipopolysaccharide-treated human peripheral blood mononuclear cells. Animal Biotechnology. 2022:1-7.Available from: doi: 10.1080/10495398.2022.2077743

20. Efimenko A, Starostina E, Kalinina N, Stolzing A. Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning. Journal of translational medicine. 2011;9:1-13.Avalable from: doi: 10.1186/1479-5876-9-10.

21. Prism G. one-way ANOVA followed by Tukey’s multiple comparison test was performed using GraphPad Prism version 7.00 for Windows. 2016.

22. Zhang J, Liu Y, Chen Y, Yuan L, Liu H, Wang J, et al. Adipose-derived stem cells: current applications and future directions in the regeneration of multiple tissues. Stem Cells International. 2020;2020. Available from: doi: 10.1155/2020/8810813.

23. Shin L, Peterson DA. Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem cells translational medicine. 2012;1(2):125-35.Available from: doi: 10.5966/sctm.2012-0031.

24. Li M, Jiang Y, Hou Q, Zhao Y, Zhong L, Fu X. Potential pre-activation strategies for improving therapeutic efficacy of mesenchymal stem cells: current status and future prospects. Stem Cell Research & Therapy. 2022;13(1):1-21. Available from: doi: 10.1186/s13287-022-02822-2.

25. Yang Y, Lee EH, Yang Z. Hypoxia-Conditioned Mesenchymal Stem Cells in Tissue Regeneration Application. Tissue Engineering Part B: Reviews. 2022. Available from: doi: 10.1089/ten.teb.2021.0145.

26. Yusoff FM, Nakashima A, Kawano K-i, Kajikawa M, Kishimoto S, Maruhashi T, et al. Implantation of Hypoxia-Induced Mesenchymal Stem Cell Advances Therapeutic Angiogenesis. Stem Cells International. 2022;2022. Available from: doi: 10.1155/2022/6795274.

27. Isik B, Thaler R, Goksu BB, Conley SM, Al-Khafaji H, Mohan A, et al. Hypoxic preconditioning induces epigenetic changes and modifies swine mesenchymal stem cell angiogenesis and senescence in experimental atherosclerotic renal artery stenosis. Stem cell research & therapy. 2021;12(1):1-13. Available from: doi: 10.1186/s13287-021-02310-z.

28. Nowak-Stępniowska A, Osuchowska PN, Fiedorowicz H, Trafny EA. Insight in Hypoxia-Mimetic Agents as Potential Tools for Mesenchymal Stem Cell Priming in Regenerative Medicine. Stem Cells International. 2022;2022. Available from: doi: 10.1155/2022/8775591.

29. Xu J, Zuo C. The Fate Status of Stem Cells in Diabetes and its Role in the Occurrence of Diabetic Complications. Frontiers in Molecular Biosciences. 2021;8:745035. Available from: doi: 10.3389/fmolb.2021.745035.

30. Gu JH, Lee JS, Kim DW, Yoon ES, Dhong ES. Neovascular potential of adipose‐derived stromal cells (ASCs) from diabetic patients. Wound Repair and Regeneration. 2012;20(2):243-52. Available from: doi: 10.1111/j.1524-475X.2012.00765.x.

31. Yin M, Zhang Y, Yu H, Li X. Role of hyperglycemia in the senescence of mesenchymal stem cells. Frontiers in Cell and Developmental Biology. 2021;9:665412. Available from: doi: 10.3389/fcell.2021.665412.

32. Oses C, Olivares B, Ezquer M, Acosta C, Bosch P, Donoso M, et al. Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: Potential application in the treatment of diabetic neuropathy. PLoS One. 2017;12(5):e0178011. Available from: doi: 10.1371/journal.pone.0178011.

33. Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death & Differentiation. 2016;23(3):369-79. Available from: doi: 10.1038/cdd.2015.158. Epub 2016 Jan 22.

34. Mursaleen L, Chan SHY, Noble B, Somavarapu S, Zariwala MG. Curcumin and N-Acetylcysteine Nanocarriers Alone or Combined with Deferoxamine Target the Mitochondria and Protect against Neurotoxicity and Oxidative Stress in a Co-Culture Model of Parkinson’s Disease. Antioxidants. 2023;12(1):130. Available from: doi: 10.3390/antiox12010130.

35. Ikeda Y, Tajima S, Yoshida S, Yamano N, Kihira Y, Ishizawa K, et al. Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function. Atherosclerosis. 2011;215(2):339-47. Available from: doi: 10.1016/j.atherosclerosis.2011.01.009.

36. Holden P, Nair LS. Deferoxamine: an angiogenic and antioxidant molecule for tissue regeneration. Tissue Engineering Part B: Reviews. 2019;25(6):461-70. Available from: doi: 10.1089/ten.TEB.2019.0111.

37. Howland MA. Risks of parenteral deferoxamine for acute iron poisoning. Journal of Toxicology:34(5):491-7. Available from: doi: 10.3109/15563659609028006.

38. Davis CK, Jain SA, Bae O-N, Majid A, Rajanikant G. Hypoxia mimetic agents for ischemic stroke. Frontiers in cell and developmental biology. 2019;6:175. Available from: doi: 10.3389/fcell.2018.00175.